Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2008

Bayer Recalls Liquid Version of Myeloid Growth Factor due to Increased Fainting Reports

  • Bayer HealthCare Pharmaceuticals reports that it will withdraw the liquid formulation of its myeloid growth factor, Leukine®, marketed in the U.S. This decision was made following discussions with the FDA in light of an increase in spontaneous reports of adverse reactions including fainting.

    Leukine is approved to reduce the incidence of infections resulting in early death following induction chemotherapy in older adults with acute myelogenous leukemia (AML). It is also used to prolong survival of patients with bone marrow graft failure or engraftment delay.

    The reported adverse reactions are correlated with the liquid Leukine 500 µg vial, which contains EDTA (edetate disodium), according to Bayer. Hence, the company plans to reformulate the liquid Leukine to eliminate EDTA. In the meantime, Bayer will increase supplies of lyophilized Leukine, which does not contain EDTA.

    The firm will establish a special access program for the currently marketed lyophilized Leukine 250 µg vial. It will be designed to prioritize the supply of the lyophilized Leukine for patients with AML and those who are experiencing bone marrow transplantation engraftment failure or delay. Through the program, Leukine therapy will continue to be supplied to patients participating in clinical studies.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »